Literature DB >> 22200621

Dihydroceramide desaturase and dihydrosphingolipids: debutant players in the sphingolipid arena.

Gemma Fabrias1, Jose Muñoz-Olaya, Francesca Cingolani, Paola Signorelli, Josefina Casas, Vincenzo Gagliostro, Riccardo Ghidoni.   

Abstract

Sphingolipids are a wide family of lipids that share common sphingoid backbones, including (2S,3R)-2-amino-4-octadecane-1,3-diol (dihydrosphingosine) and (2S,3R,4E)-2-amino-4-octadecene-1,3-diol (sphingosine). The metabolism and biological functions of sphingolipids derived from sphingosine have been the subject of many reviews. In contrast, dihydrosphingolipids have received poor attention, mainly due to their supposed lack of biological activity. However, the reported biological effects of active site directed dihydroceramide desaturase inhibitors and the involvement of dihydrosphingolipids in the response of cells to known therapeutic agents support that dihydrosphingolipids are not inert but are in fact biologically active and underscore the importance of elucidating further the metabolic pathways and cell signaling networks involved in the biological activities of dihydrosphingolipids. Dihydroceramide desaturase is the enzyme involved in the conversion of dihydroceramide into ceramide and it is crucial in the regulation of the balance between sphingolipids and dihydrosphingolipids. Furthermore, given the enzyme requirement for O₂ and the NAD(P)H cofactor, the cellular redox balance and dihydroceramide desaturase activity may reciprocally influence each other. In this review both dihydroceramide desaturase and the biological functions of dihydrosphingolipids are addressed and perspectives on this field are discussed. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22200621     DOI: 10.1016/j.plipres.2011.12.002

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  36 in total

1.  Multiple actions of doxorubicin on the sphingolipid network revealed by flux analysis.

Authors:  Justin M Snider; Magali Trayssac; Christopher J Clarke; Nicholas Schwartz; Ashley J Snider; Lina M Obeid; Chiara Luberto; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-12-20       Impact factor: 5.922

2.  Renal sulfatides: sphingoid base-dependent localization and region-specific compensation of CerS2-dysfunction.

Authors:  Christian Marsching; Mariona Rabionet; Daniel Mathow; Richard Jennemann; Christiane Kremser; Stefan Porubsky; Christian Bolenz; Klaus Willecke; Hermann-Josef Gröne; Carsten Hopf; Roger Sandhoff
Journal:  J Lipid Res       Date:  2014-09-29       Impact factor: 5.922

Review 3.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

4.  New fluorogenic probes for neutral and alkaline ceramidases.

Authors:  Mireia Casasampere; Núria Bielsa; Daniel Riba; Laura Bassas; Ruijuan Xu; Cungui Mao; Gemma Fabriàs; José-Luis Abad; Antonio Delgado; Josefina Casas
Journal:  J Lipid Res       Date:  2019-03-29       Impact factor: 5.922

Review 5.  Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Authors:  Christina Voelkel-Johnson; James S Norris; Shai White-Gilbertson
Journal:  Adv Cancer Res       Date:  2018-06-20       Impact factor: 6.242

Review 6.  Dihydroceramides: From Bit Players to Lead Actors.

Authors:  Monowarul Mobin Siddique; Ying Li; Bhagirath Chaurasia; Vincent A Kaddai; Scott A Summers
Journal:  J Biol Chem       Date:  2015-05-06       Impact factor: 5.157

7.  Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling.

Authors:  Monowarul M Siddique; Ying Li; Liping Wang; Jianhong Ching; Mainak Mal; Olga Ilkayeva; Ya Jun Wu; Boon Huat Bay; Scott A Summers
Journal:  Mol Cell Biol       Date:  2013-04-01       Impact factor: 4.272

8.  Individual profiles of free ceramide species and the constituent ceramide species of sphingomyelin and neutral glycosphingolipid and their alteration according to the sequential changes of environmental oxygen content in human colorectal cancer Caco-2 cells.

Authors:  Kouji Tanaka; Keiko Tamiya-Koizumi; Masaki Yamada; Takashi Murate; Reiji Kannagi; Mamoru Kyogashima
Journal:  Glycoconj J       Date:  2013-12-06       Impact factor: 2.916

9.  Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids.

Authors:  Anna Caretti; Michele Vasso; Fabiola Tecla Bonezzi; Andrea Gallina; Marco Trinchera; Alice Rossi; Raffaella Adami; Josefina Casas; Monica Falleni; Delfina Tosi; Alessandra Bragonzi; Riccardo Ghidoni; Cecilia Gelfi; Paola Signorelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-24       Impact factor: 3.000

10.  Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II.

Authors:  Francesca Cingolani; Mireia Casasampere; Pol Sanllehí; Josefina Casas; Jordi Bujons; Gemma Fabrias
Journal:  J Lipid Res       Date:  2014-05-29       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.